A drug used to treat hepatitis can help reduce ALS's progress. It is also known as the Igerig disease.
A protein that is called the tubeville drug, SOD1, is targeted at most ALS patients.
"We suggest that TILDDUIDINE helps to reduce SOD1's poisoning, which will help improve the health of the motor neurons and improve mobility," said a biologist and researcher Ted Allison.
Current therapeutic modes Decreased Disease was less and less slow. These findings would improve the treatment of patients who suffer ALS in improving and improving their standard of living.
Computer simulations used research team to identify drugs that target SOD1 protein. From this shortlist, using the telebidine found the most probable experiments from animals and tested them.
"ALS can not understand better," says the protagonist Michel Dual, And recently completed their PhD part Faculty of Medicine & Dentistry MD / PhD Program By Alexis.
"We do not know what is wrong with motor neurons or how bad software affects SOD1 poisoning, and the ALS research team focuses on understanding ALS and promoting treatment therapies."
Telebududin explains how effective the reduction of ALS progress in models of other animals.
It is particularly exciting to note that clinical trials in human beings may be going on more quickly, since it is already known that drugs are used for medication for hepatitis patients and therefore are prescribed for health control.
"It has been proven to be safe for patients already in use, and it's possible to use this in a new clinical setting against ALS," said Allison.
The research was done in cooperation with Kovalenko Lab National Research Council On U campus.
Research, "Tiproopan 32 Middle Levels Model of Toxicity ALS in SOD1 Video Motor Neurone and Promise Aim for Small Molecular Therapy, "Published Neurobiology of Disease.
& # 39;);
ppLoadLater.placeholderFBSDK = pploadLater.placeholderFBSDK.join (" n");